
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical is well positioned by a growing ADHD franchise and a resilient pain portfolio, with Jornay PM sales of $51.9M, up 24% year over year, and total ADHD revenue of $78.4M, up 33% sequentially. Its expanded 190-rep salesforce, broader formulary access, and successful Azstarys integration support the view that script growth can accelerate while management guides to 2026 Jornay PM sales of $190M-$200M and Azstarys sales of $65M-$75M. The company also appears undervalued relative to its cash-generating pain assets, as Belbuca produced $57.7M in revenue and patent protection through 2032 may delay generic erosion, helping fund share repurchases and future business development.
Bears say
Collegium Pharmaceutical is facing a deteriorating fundamental setup because its pain franchise is under pressure from generic competition, lower net pricing on the Hikma authorized generics, and shrinking opioid script volumes, with the total Nucynta franchise falling to $35.2M in 2Q26, down 24% year over year. Management also cut 2026 revenue guidance by $40M for Nucynta, while Belbuca still carries meaningful uncertainty around potential generic entry beginning in 2027, creating a difficult outlook for a business that relies on exclusivity and reimbursement support. Although Jornay PM and Azstarys offer longer-term growth visibility, the company still faces commercialization, REMS, and third-party supply risks, and those newer assets may not offset erosion across the core pain portfolio.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Collegium Pharmaceutical (COLL) Forecast
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares